At the news
? NEUTRALIMPACT 3/10 EFFECT filed Jul 14, 2026 at 00:15 ET
Q32 Bio's S-3 shelf registration (File No. 333-297027) became effective on July 13, 2026, allowing the company to sell equity or debt securities at any time. As a pre-revenue biotech with significant operating losses, this creates potential dilution overhang, though no immediate offering has been announced.
- S-3 shelf registration became effective on July 13, 2026.
- Company can now issue an unlimited amount of securities (senior/subordinated debt, equity, etc.).
- Q32 Bio is a pre-revenue biotech with no product revenue and substantial operating losses.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access